Status summary
- • 7 resolved — Wegovy, Zepbound, Ozempic, Mounjaro, Saxenda, Rybelsus, Trulicity
- • 0 current shortage
- • 1 manufacturer-discontinued — Victoza (liraglutide 1.2/1.8 mg)
- • 2 active recalls (past 12 months) — see per-drug detail below
Per-drug status
Wegovy(Novo Nordisk)
resolvedFDA database today: not on the shortage list (checked 2026-07-26)
Resolved: 2025-02-21 · All dose strengths (0.25, 0.5, 1, 1.7, 2.4 mg) removed from FDA shortage list after sustained supply recovery.
FDA Recalls (past 12 months): 2
- · 20251219: Presence of Particulate Matter: Hair was found in a prefilled syringe
- · 20251219: Presence of Particulate Matter: Hair was found in a prefilled syringe
Ozempic(Novo Nordisk)
resolvedFDA database today: not on the shortage list (checked 2026-07-26)
Resolved: 2024-12-19 · All dose strengths resolved late 2024. Pharmacy fills generally available.
Zepbound(Eli Lilly)
resolvedFDA database today: not on the shortage list (checked 2026-07-26)
Resolved: 2024-12-19 · Single-dose vial and KwikPen formulations resolved December 2024.
Mounjaro(Eli Lilly)
resolvedFDA database today: not on the shortage list (checked 2026-07-26)
Resolved: 2024-12-19 · All dose strengths (2.5-15 mg) resolved late 2024.
Saxenda(Novo Nordisk)
resolvedFDA database today: listed, no supply constraint reported (checked 2026-07-26)
Resolved: 2024-05-31 · Resolved earlier than Wegovy/Ozempic; lower demand profile.
Rybelsus(Novo Nordisk)
resolvedFDA database today: listed, no supply constraint reported (checked 2026-07-26)
Resolved: 2024-07-15 · Oral semaglutide tablets — generally available.
Trulicity(Eli Lilly)
resolvedFDA database today: not on the shortage list (checked 2026-07-26)
Resolved: 2024-08-30 · Lower-demand GLP-1 with stable supply.
Victoza(Novo Nordisk)
discontinuedFDA database today: listed with constrained supply (checked 2026-07-26)
Discontinued: 2024-04-01
Manufacturer discontinued Victoza (liraglutide 1.2/1.8 mg). Saxenda (liraglutide 3.0 mg for weight) remains. Patients should consult prescriber for alternative.
What this means for patients
The 2025 resolution of GLP-1 shortages means brand-name medications (Wegovy, Zepbound, Mounjaro, Ozempic) are generally available at most pharmacies. Compounded GLP-1 production legal basis narrowed post-resolution — patients on compounded products may face increasing pressure to switch to FDA-approved alternatives as the regulatory environment tightens.
For patients who've been managing their treatment around shortages: this is the right time to discuss longer-term planning with your prescriber, especially if you've been bouncing between formulations or pharmacies.
If shortages return
Get FDA shortage-status updates by email below, or opt into price-drop alerts on specific drugs — the same subscriber record covers both.
The GLP1Zoom weekly
GLP-1 price moves & FDA news, in your inbox.
Weekly editorial round-up — partner price changes, new FDA labels, drug-shortage updates, and one independent take. No medical advice; no spam.
Sources
- FDA Drug Shortage Database
- FDA Drug Shortages program page
- Manufacturer-issued supply communications (Novo Nordisk, Eli Lilly)
Status reviewed manually against FDA Drug Shortage Database. Information current as of 2026-06-02. Pharmacy-level availability may differ from FDA-status from distribution timing. Always confirm with your pharmacy before assuming availability. Full disclaimer.